- Fee assured
- Awaiting verification
- Movement disorders
Dr Gary Hotton qualified from University College and Middlesex School of Medicine in 1995. His general medical training was undertaken at Dundee Royal Infirmary and the Royal Free Hospital. Following this he spent seven years in research at Kings College Hospital and Imperial College London. He then returned to specialist training in London and joined the specialist register in May 2010.
Currently Dr Hotton is a Consultant Neurologist and divides his time between the National Hospital for Neurology and Neurosurgery (NHNN) and The North Middlesex Hospital. At the NHNN he has a specialist neuro-oncology clinic and is a core member of the neuro-oncology multidisciplinary team.
Areas of interest
Brain tumours; Neuro-Oncology, headache; botulinum toxin injections for dystonia and headache
Current NHS consultant posts held
Consultant Neurologist and Neuro-oncologist at the National Hospital for Neurology and Neurosurgery
Consultant Neurologist at the North Middlesex Hospital
Dr Hotton current research interests are in the imaging and optimisation of the medical management of patients with central nervous system tumors.
2006 William Koller Award for innovative research (Movement Disorder Society)
Gill S, Patel N, Hotton G, O’Sullivan K, McCarter R, Bunnage M, Brooks D, Svendson C, Heywood P. Direct Infusion of glial cell line derived neurotrophic factor (GDNF) in Parkinson’s Disease. Nat Med. 2003:9:589-595.
Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 2005;11:703-704.
Gerhard A, Pavese A, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ. In vivo imaging of microglial activation with [11C] (R) -PK11195 PET in idiopathic Parkinson’s disease. Neurobiology of Disease 2006; 21: 404-12.
Edison P, Archer H, Hinz R, Hammers A, Pavese N, Tai Y, Hotton G, Fox N, Kennedy A, Rossor M, Brooks DJ. Amyloid deposition and metabolic dysfunction in Alzheimer’s disease and mild cognitive impairment: An 11C-PIB and 18F-FDG PET study. Neurology 2007; 68: 501-8.
Thobois S, Hotton G, Pinto S, Wilkinson L, Limousin-Dowsey P, Brooks DJ, Jahanshahi M. In Parkinson’s disease, subthalamic nucleus stimulation alters pallidal coupling with prefrontal, cingulate, and temporal cortices during random number generation. JCBFM 2007; 27: 1173-84.
Sawamoto N, Piccini P, Hotton G, Pavese N Thielmans K, Brooks DJ. Cognitive deficits and striato-frontal dopamine release in Parkinson’s disease. Brain. 2008;131:1294-1302.
Hotton G and Clough C. Other Drug Related Movement Disorders in Drug Related Movement Disorders ed. K. Sethi. Marcel Decker 2004
Hotton G. Anti-epileptic treatment for patients with brain tumors and epilepsy . Key Opinions in Medicine.
Web Pages / Web based leaning tools
Hotton G and Chauhuri R. Parkinson’s Disease. www.netdoctor.co.uk
Hotton G. Management of Patients with CNS Tumors. www.ebrainjnc.com
- BSc University College London 1992
- MB BS University College London 1995
- MRCP Royal College of Physicians 2008
- MD University of London 2008
- Speciality Certificate in Neurology Royal College of Physicians 2009
Reference number 4203364
Affiliations / memberships
Association of British Neurologists
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.